In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...

The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...

UW Health's Dr. Bill Hartman discusses ways to slow down aging, a study that says high school student's aren't getting enough ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

In trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer ...